Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 46

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 46
---
 are intended to align the interest of our executives with those of our shareholders because the value realized, if any, by the recipient from an equity award depends upon the increases in the price of our common shares. Please read the “Executive Compensation” section of this Proxy Statement for additional details about our executive compensation programs, including information about the fiscal year 2024 compensation of our named executive officers.

We are asking our shareholders to indicate their support for our named executive officer compensation as described in the “Executive Compensation” section of this Proxy Statement. This proposal, sometimes called “say-on-pay,” gives our shareholders the opportunity to express their views on our named executive officers’ compensation. Accordingly, our Board is asking our shareholders to cast a non-binding advisory vote “FOR” the following resolution at the Meeting:

“RESOLVED, that Lineage’s shareholders approve, on an advisory basis, the compensation paid to Lineage’s named executive officers, as disclosed in Lineage’s Proxy Statement for the 2025 annual meeting of shareholders pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion.”

Our shareholders’ vote on this proposal is only advisory and is not binding on Lineage, our Compensation Committee, or our Board. However, our Compensation Committee, which is responsible for designing and administering our executive compensation program, values the opinions expressed by our shareholders in their votes on this proposal and will consider the outcome of the vote when making future compensation decisions for named executive officers.

<div align='center'>OUR BOARD RECOMMENDS A VOTE “FOR” THIS PROPOSAL

-36-

PROPOSAL 4 - APPROVAL OF AN AMENDMENT TO THE

LINEAGE CELL THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN</div>

We are asking our shareholders to approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan (the “2021 Plan”) that, if approved, will make an additional 19,500,000 common shares available for issuance under the 2021 Plan (the “Plan Amendment”).

The 2021 Plan was approved by our shareholders at our 2021 annual meeting. When we solicited shareholder approval of the 2021 Plan, we stated that, absent any unforeseen circumstances, we anticipated seeking shareholder approval of an increase in the number of shares available for issuance thereunder in 2023. In 2023, we solicited, and obtained, shareholder approval of an amendment to the